XTL Biopharmaceuticals Ltd. announced on December 30, 2024, its acquisition of The Social Proxy Ltd., with a deal valued at $5.8 million, paying $430,000 and issuing 1,864,790 shares representing 21.16% of XTL post-transaction. The acquisition aims to enhance XTL's asset portfolio with high-potential assets, and it follows the approval of a $1.5 million private placement to support this transaction.